Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma
E. Josue Ruiz, Adán Pinto-Fernández, A.P. Turnbull, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu, Runsen Jin, Yan Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 95
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer
Jessica K. Nelson, May Zaw Thin, Theodore Evan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 58
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Hui Ming, Bowen Li, Jingwen Jiang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 30
Recent advances in the development of deubiquitinases inhibitors as antitumor agents
Lili Zheng, Liting Wang, Ye-Wei Pang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116161-116161
Closed Access | Times Cited: 12
Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
Can Cheng, Hanhui Yao, Heng Li, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 4, pp. 1624-1643
Open Access | Times Cited: 8
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck
Jia Luo, Justin A. Bishop, Steven G. DuBois, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 1
Structural basis for the bi-specificity of USP25 and USP28 inhibitors
J. Patzke, Florian Sauer, Radhika K. Nair, et al.
EMBO Reports (2024) Vol. 25, Iss. 7, pp. 2950-2973
Open Access | Times Cited: 7
TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer
Wenlong Ye, Long Huang, Xiaoqin Yang, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 42
Open Access | Times Cited: 7
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness
Tengyang Ni, Zewen Chu, Tao Li, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 6, pp. 1005-1018
Open Access | Times Cited: 15
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development
Xiaoya Ren, Menglong Jiang, Peng Ding, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 15
USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer
Carina R. Maier, Oliver Hartmann, Cristian Prieto‐Garcia, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 7, pp. 1710-1725
Open Access | Times Cited: 15
The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer
Jun‐O Jin, Nidhi Puranik, Quyen Thu Bui, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9629-9629
Open Access | Times Cited: 30
USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma
Cristian Prieto‐Garcia, Ines Tomašković, Varun Jayeshkumar Shah, et al.
Cells (2021) Vol. 10, Iss. 10, pp. 2652-2652
Open Access | Times Cited: 28
The Ubiquitin–Proteasome System in Tumor Metabolism
Jie Wang, Yuandi Xiang, Mengqi Fan, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2385-2385
Open Access | Times Cited: 12
Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects
Mohamad Bakkar, Sara I. Khalil, Komal Bhayekar, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 240-240
Open Access
USP28-mediated deubiquitination of FOXK1 activates the Hippo signaling pathway to regulate cell proliferation and radiosensitivity in lung cancer
Yimei Meng, Yunhong Xu, Anchen Qiu, et al.
Life Sciences (2025), pp. 123483-123483
Open Access
USP28 Knockdown and Small Molecule Inhibitors Promote KRT1 Destabilization and Sensitize Hepatocellular Carcinoma Cells to Sorafenib
Zilin Li, Yan Wang, Jiahui Hu, et al.
Experimental Cell Research (2025), pp. 114558-114558
Closed Access
USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer
Fang Han, Gonghua Qi, Rongrong Li, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Suppression of Cancer Cell Stemness and Drug Resistance via MYC Destabilization by Deubiquitinase USP45 Inhibition with a Natural Small Molecule
Xiao Tu, Chuncheng Li, Wen Sun, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 930-930
Open Access | Times Cited: 10
Structure-based discovery of potent USP28 inhibitors derived from Vismodegib
Di Zhou, Zhuo Xu, Yaodong Huang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115369-115369
Closed Access | Times Cited: 9
Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer
Yiqiong Song, Longhao Wang, Yuanyuan Zheng, et al.
APOPTOSIS (2024) Vol. 29, Iss. 9-10, pp. 1793-1809
Open Access | Times Cited: 3
Landscape of targeted therapies for lung squamous cell carcinoma
Qiuxuan Chen, Xiao-Shuo Zheng, Weiting Cheng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Ubiquitin‐specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma
Xiao Sun, Mengjiao Cai, Lingzhi Wu, et al.
Cancer Science (2022) Vol. 113, Iss. 10, pp. 3463-3475
Open Access | Times Cited: 15
ABPP-HT - High-Throughput Activity-Based Profiling of Deubiquitylating Enzyme Inhibitors in a Cellular Context
Hannah B. L. Jones, Raphael Heilig, Román Fischer, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top